Megan Hall

Megan Hall

Auto-generated profile, based on publicly available information

Megan Hall

Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2023 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
JGJosé García-Tirado
José García-Tirado
OVOrianne Villard
Orianne Villard
MHMegan Hall
Megan Hall
ABAlessandro Bisio
Alessandro Bisio
LGLinda Gonder-Frederick
Linda Gonder-Frederick
Individuals with type 1 diabetes of minoritized race-ethnicities and low-socioeconomic status (SES) do not access nor use automated insulin delivery (AID) technology at equal rates compared to their non-Hispanic White (NHW) and high SES counterparts. Using four AID trials (n=292), we ran linear mixed models to compare glycemic outcomes using race/ethnicity, education, and income. These trials overrepresented NHW (83%), high-income (91%), and highly educated (86%) populations. By education, participants with <bachelor's degree had worse baseline glycemic control than those with ≥bachelor's degree as per HbA1c: 7.83% vs. 7.25% (p<0.001), time-in-range: 50.1% vs. 61.2% (p180 mg/dL: 46.2% vs. 34.5% (p<0.001). These differences disappeared following AID use. By race/ethnicity and income groups, there were no differences in baseline glycemic control. While baseline glycemic control tended to be worse for underrepresented populations, AID glycemic efficacy was approximately equivalent. These results suggest improving accessibility to AID could equalize glycemic outcome disparities.